JEWJITSU PEPTIDES roundup: directional membrane coatings, oral peptide formulations, and allergen immunotherapy advances

The first paper reports a directional membrane‑coating approach developed to preserve the native orientation of cell membranes during coating of drug carriers. The authors screened a peptide that binds phosphatidylserine (PS) exposed on the inner leaflet and attached that peptide to drug‑loaded nanocarriers so that the membrane would assemble with CD47 facing outward and PS retained internally. They applied the method to red blood cell membrane‑coated bufalin liposomes (BF/Lip‑Pep@RBC) and report that the engineered carriers retained outward CD47 display and internalized PS, reduced macrophage uptake relative to a non‑directional coating condition, and extended circulation half‑life. The abstract gives quantitative findings for macrophage uptake reduction and half‑life extension and describes antitumor activity and biosafety in a breast cancer model. The report is preclinical and focused on a specific engineered formulation; broader translation, reproducibility across cell types, scale‑up, and clinical relevance require further validation as noted by the authors' experimental scope.

The second study compares the impact of dosage form and two permeation enhancers, sodium salcaprozate (SNAC) and sodium decanoate (C10), on oral absorption of the peptide octreotide in a rat oral‑gavage model. The team developed mini‑tablets containing octreotide plus either SNAC or C10 and evaluated disintegration in small biorelevant liquid volumes, finding that PE type and volume only slightly affected disintegration time but that results depended on experimental setup. In pharmacokinetic experiments, plasma octreotide concentrations were higher when a PE was present for both solution and mini‑tablet administrations versus controls without PE. SNAC produced a greater relative bioavailability than C10 and control in these rat gavage experiments, and the authors report fold‑changes in relative bioavailability for solution and mini‑tablet formats under different liquid volumes. The study documents formulation‑ and PE‑dependent PK differences in a preclinical model; oral gavage in rats and the specific mini‑tablet designs limit direct extrapolation to human oral dosing and require additional translational work.

The third article is a narrative review of recent advances in allergen immunotherapy (AIT) for IgE‑mediated allergic diseases. The review summarizes current understanding of immunological mechanisms, highlighting roles for regulatory T and B cells, innate lymphoid cells, and blocking antibodies (IgG4, IgA), and surveys novel vaccine approaches such as recombinant and hypoallergenic derivatives, virus‑like particle conjugates, and peptide‑based strategies. The authors discuss available and candidate biomarkers for predicting or monitoring AIT response (for example sIgE/tIgE ratios, basophil activation tests, and cellular markers), clinical evidence across allergic rhinitis, asthma, atopic dermatitis and emerging food allergy applications, and combination approaches pairing AIT with biologics such as anti‑IgE or anti‑IL‑4/IL‑4R. The review also notes persistent challenges including patient selection, treatment duration, and extract standardization, and calls for further work on predictive biomarkers and optimized regimens. As a review, it synthesizes varied sources and highlights research directions rather than presenting new primary clinical trial data.